Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-08-17 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
首次公开发行部分限售股上市流通公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares following the company's initial public offering (IPO). It details the number of shares becoming tradable, the lock-up periods, shareholder commitments, and regulatory approvals. The document references regulatory approvals from the China Securities Regulatory Commission and the Shanghai Stock Exchange, and includes commitments from major shareholders about share lock-up and reduction plans. It does not contain financial statements or performance data, nor is it a report or presentation. The document is a formal announcement about the capital market event of restricted shares becoming freely tradable, which fits the category of Share Issue/Capital Change announcements rather than a full financial report or other categories.
2025-08-17 Chinese
关于控股股东自愿承诺不减持公司股份的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding a voluntary commitment by its controlling shareholder not to reduce their shareholding for 24 months. It includes details about the shareholder's current holdings and the commitment period. There is no financial data, report, or detailed analysis present. The document is a regulatory announcement about shareholding behavior, not a financial report or management information. This fits best under the category of Major Shareholding Notification (MRQ), which covers notifications of changes or commitments related to significant share ownership levels.
2025-08-17 Chinese
国泰海通证券股份有限公司关于上海宣泰医药科技股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 85% confidence The document is a sponsor’s verification opinion (“核查意见”) regarding the unlocking/listing of IPO restricted shares for Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It describes share types, volumes, lock-up commitments and the sponsor’s conclusions. It is not a financial report (no financial statements), not a board or management change, neither an earnings release nor an investor presentation, nor a merger, dividend, or share buyback. It is a regulatory announcement of share circulation changes that does not fit other specific categories. Therefore, it falls under the catch-all Regulatory Filings category (RNS).
2025-08-17 Chinese
关于使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the use of part of idle raised funds for cash management. It details the board's approval, the amount and duration of funds to be used, investment types, risk control measures, and opinions from the audit committee and sponsor institution. The document is about the company's use of idle raised funds, not a full financial report or audit. It is a regulatory announcement related to capital management and fundraising usage, not an annual report, interim report, or earnings release. The document length is 3660 characters, relatively short and focused on a specific financing-related update. Therefore, it fits best under Capital/Financing Update (CAP).
2025-08-08 Chinese
国泰海通证券股份有限公司关于上海宣泰医药科技股份有限公司使用部分闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 81% confidence The document is a sponsor’s due‐diligence “核查意见” on the use of idle IPO proceeds by Shanghai Xuantai Pharma, detailing regulatory references, board approvals, and cash‐management plans. It is not a full financial report (e.g. Annual or Interim Report), not an earnings release, not a management discussion, nor a transaction in own shares. It is essentially a compliance/regulatory disclosure required by the stock exchange. Therefore it falls under the general Regulatory Filings category (RNS).
2025-08-08 Chinese
自愿披露关于全资子公司通过欧盟GMP认证的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding its wholly-owned subsidiary obtaining EU GMP certification. It includes details about the certificate, issuing authority, and the impact on the company. The document is short (941 characters) and serves as an announcement of a regulatory compliance event rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. It fits best under Regulatory Filings (RNS) as a general regulatory announcement about compliance and certification.
2025-07-17 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.